氟达拉滨联合吡柔比星治疗复发难治性惰性非霍奇金淋巴瘤  

Fludarabine combined with pirarubicin chemotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma

作　　者：王华庆[1] 邱立华[1] 钱正子[1] 李维[1] 孟祥睿[1] 侯芸[1] 宋拯[1] 赵静[1] 崔秀珍[1] 郝希山[1] 

机构地区：[1]天津医科大学附属肿瘤医院淋巴肿瘤科天津市肿瘤防治重点实验室,300060

出　　处：《白血病．淋巴瘤》2009年第10期609-611,615,共4页Journal of Leukemia & Lymphoma

摘　　要：目的探讨FT（氟达拉滨及吡柔比星）方案治疗复发难治惰性非霍奇金淋巴瘤（NHL）的有效性和安全性。方法复发难治惰性NHL40例，采用FT方案化疗，28d为1个周期，共6个周期。FND（氟达拉滨、米托蒽醌及地塞米松）方案治疗惰性NHL的数据为对照。结果FT组40例共治疗228个周期，有效率62．5％，中位无进展生存期超过20个月，2年总生存率70．0％，与对照组相似（P〉0．05）；不良反应以中性粒细胞减少（80．0％）最为常见，但Ⅲ～Ⅳ度中性粒细胞减少症和肺炎的发生率均低于对照组，分别为12．5％、29．0％和2．5％、23．0％（P〈0．05）。结论FT方案治疗复发难治惰性NHL安全有效，骨髓抑制轻，感染发生率低。Objective To evaluate the efficacy and safety of fludarabine and pirarubicin （FT） regimen in the treatment of refractory or relapsed indolent non-Hodgkin lymphoma （NHL）. Methods A total of 40 patients with relapsed or refractory indolent NHL were treated with FT regimen, one cycle for 28 days, total 6 cycles. The data of indolent NHL patients treated with fludarabine, noventrone and dexamethasone （FND） regimen were collected as control. Results 40 patients were given 228 cycles chemotherapy, overall response rate was 62.5 %, median progression-free survival was more than 20 months and 2 years overall survival rate was 70.0 %. The main toxicities was leucopenia （80.0 %）, but the incidence of WHO Ⅲ-Ⅳ leucopenia and pneumonia was less than that of in the control group, the rate were 12.5 % vs 29.0 % and 2.5 % vs 23.0 % respectively （P 〈0.05）. Conclusion The efficacy of FT regimen was as good as FND regimen, but the incidence of leucopenia and pneumonia by Ⅲ-Ⅳ was lower in FT group than in FND group. So the FT regimen was an effective and safe second-line salvage regimen for relapsed or refractory indolent non-Hodgkin lymphoma.

关 键 词：淋巴瘤 非霍奇金 氟达拉滨 吡柔比星 

分 类 号：R733.1[医药卫生—肿瘤] R521[医药卫生—临床医学]